Titre : Podophyllotoxine

Podophyllotoxine : Questions médicales fréquentes

Termes MeSH sélectionnés :

DNA Copy Number Variations
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Podophyllotoxine : Questions médicales les plus fréquentes", "headline": "Podophyllotoxine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Podophyllotoxine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-25", "dateModified": "2025-04-21", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Podophyllotoxine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "1,2,3,4-Tétrahydro-naphtalènes", "url": "https://questionsmedicales.fr/mesh/D013764", "about": { "@type": "MedicalCondition", "name": "1,2,3,4-Tétrahydro-naphtalènes", "code": { "@type": "MedicalCode", "code": "D013764", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.638.960" } } }, "about": { "@type": "MedicalCondition", "name": "Podophyllotoxine", "alternateName": "Podophyllotoxin", "code": { "@type": "MedicalCode", "code": "D011034", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Srinivas Nerella", "url": "https://questionsmedicales.fr/author/Srinivas%20Nerella", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Kakatiya University, Warangal, India." } }, { "@type": "Person", "name": "Shravankumar Kankala", "url": "https://questionsmedicales.fr/author/Shravankumar%20Kankala", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Kakatiya University, Warangal, India." } }, { "@type": "Person", "name": "Ya-Jie Tang", "url": "https://questionsmedicales.fr/author/Ya-Jie%20Tang", "affiliation": { "@type": "Organization", "name": "State Key Laboratory of Microbial Technology, Shandong University, Qingdao 266237, Shandong, China." } }, { "@type": "Person", "name": "George Angelov", "url": "https://questionsmedicales.fr/author/George%20Angelov", "affiliation": { "@type": "Organization", "name": "Institute of Chemical Engineering, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria." } }, { "@type": "Person", "name": "Dan-Li Tian", "url": "https://questionsmedicales.fr/author/Dan-Li%20Tian", "affiliation": { "@type": "Organization", "name": "Tianjin First Central Hospital Tianjin 300192,China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Mapping recurrent mosaic copy number variation in human neurons.", "datePublished": "2024-05-17", "url": "https://questionsmedicales.fr/article/38760338", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41467-024-48392-0" } }, { "@type": "ScholarlyArticle", "name": "A pan-cancer landscape of pathogenic somatic copy number variations.", "datePublished": "2023-10-18", "url": "https://questionsmedicales.fr/article/37858853", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jbi.2023.104529" } }, { "@type": "ScholarlyArticle", "name": "Copy number variations in SPAST and ATL1 are rare among Brazilians.", "datePublished": "2023-01-15", "url": "https://questionsmedicales.fr/article/36537231", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/cge.14280" } }, { "@type": "ScholarlyArticle", "name": "Copy number variation alters local and global mutational tolerance.", "datePublished": "2023-08-31", "url": "https://questionsmedicales.fr/article/37652668", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1101/gr.277625.122" } }, { "@type": "ScholarlyArticle", "name": "Contribution of copy number variations to the risk of severe eating disorders.", "datePublished": "2022-06-20", "url": "https://questionsmedicales.fr/article/35611833", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/pcn.13430" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés polycycliques", "item": "https://questionsmedicales.fr/mesh/D011083" }, { "@type": "ListItem", "position": 3, "name": "Hydrocarbures aromatiques polycycliques", "item": "https://questionsmedicales.fr/mesh/D011084" }, { "@type": "ListItem", "position": 4, "name": "Naphtalènes", "item": "https://questionsmedicales.fr/mesh/D009281" }, { "@type": "ListItem", "position": 5, "name": "1,2,3,4-Tétrahydro-naphtalènes", "item": "https://questionsmedicales.fr/mesh/D013764" }, { "@type": "ListItem", "position": 6, "name": "Podophyllotoxine", "item": "https://questionsmedicales.fr/mesh/D011034" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Podophyllotoxine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Podophyllotoxine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Podophyllotoxine", "description": "Comment diagnostiquer une infection par HPV ?\nQuels tests sont utilisés pour les verrues ?\nLes biopsies sont-elles nécessaires pour les verrues ?\nQuels signes indiquent une infection virale ?\nComment différencier les verrues des autres lésions ?", "url": "https://questionsmedicales.fr/mesh/D011034?mesh_terms=DNA+Copy+Number+Variations&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Podophyllotoxine", "description": "Quels sont les symptômes des verrues ?\nLes verrues sont-elles contagieuses ?\nLes verrues peuvent-elles causer des douleurs ?\nY a-t-il des symptômes associés à l'utilisation de podophyllotoxine ?\nLes verrues peuvent-elles disparaître sans traitement ?", "url": "https://questionsmedicales.fr/mesh/D011034?mesh_terms=DNA+Copy+Number+Variations&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Podophyllotoxine", "description": "Comment prévenir les verrues ?\nLes vaccins peuvent-ils prévenir les verrues ?\nFaut-il éviter les lieux publics ?\nLes verrues peuvent-elles réapparaître après traitement ?\nComment renforcer le système immunitaire ?", "url": "https://questionsmedicales.fr/mesh/D011034?mesh_terms=DNA+Copy+Number+Variations&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Podophyllotoxine", "description": "Comment la podophyllotoxine est-elle administrée ?\nQuels sont les effets de la podophyllotoxine ?\nY a-t-il des alternatives à la podophyllotoxine ?\nCombien de temps faut-il pour voir des résultats ?\nLa podophyllotoxine est-elle sûre pour tous ?", "url": "https://questionsmedicales.fr/mesh/D011034?mesh_terms=DNA+Copy+Number+Variations&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Podophyllotoxine", "description": "Quelles complications peuvent survenir avec les verrues ?\nLes verrues peuvent-elles causer des cicatrices ?\nY a-t-il des risques d'allergies à la podophyllotoxine ?\nLes verrues peuvent-elles se propager à d'autres parties du corps ?\nLes verrues peuvent-elles être cancéreuses ?", "url": "https://questionsmedicales.fr/mesh/D011034?mesh_terms=DNA+Copy+Number+Variations&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Podophyllotoxine", "description": "Qui est le plus à risque de développer des verrues ?\nLes personnes immunodéprimées sont-elles plus à risque ?\nLe contact avec des verrues augmente-t-il le risque ?\nLes personnes ayant des antécédents de verrues sont-elles à risque ?\nLes verrues sont-elles plus fréquentes chez certaines ethnies ?", "url": "https://questionsmedicales.fr/mesh/D011034?mesh_terms=DNA+Copy+Number+Variations&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection par HPV ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par examen clinique et tests de dépistage comme le Pap test." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour les verrues ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les verrues sont généralement diagnostiquées par inspection visuelle, sans tests spécifiques." } }, { "@type": "Question", "name": "Les biopsies sont-elles nécessaires pour les verrues ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "En général, les biopsies ne sont pas nécessaires, sauf si le diagnostic est incertain." } }, { "@type": "Question", "name": "Quels signes indiquent une infection virale ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des lésions cutanées, démangeaisons ou douleurs peuvent indiquer une infection virale." } }, { "@type": "Question", "name": "Comment différencier les verrues des autres lésions ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les verrues sont généralement rugueuses, en relief et peuvent avoir des points noirs à leur surface." } }, { "@type": "Question", "name": "Quels sont les symptômes des verrues ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les verrues peuvent provoquer des démangeaisons, des douleurs et une texture rugueuse." } }, { "@type": "Question", "name": "Les verrues sont-elles contagieuses ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les verrues peuvent se propager par contact direct ou indirect avec la peau infectée." } }, { "@type": "Question", "name": "Les verrues peuvent-elles causer des douleurs ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Certaines verrues, surtout plantaires, peuvent être douloureuses lors de la marche." } }, { "@type": "Question", "name": "Y a-t-il des symptômes associés à l'utilisation de podophyllotoxine ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des irritations cutanées, rougeurs ou douleurs peuvent survenir après application." } }, { "@type": "Question", "name": "Les verrues peuvent-elles disparaître sans traitement ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines verrues peuvent disparaître spontanément, mais cela peut prendre du temps." } }, { "@type": "Question", "name": "Comment prévenir les verrues ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Évitez le contact direct avec des verrues et maintenez une bonne hygiène des mains." } }, { "@type": "Question", "name": "Les vaccins peuvent-ils prévenir les verrues ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Le vaccin contre le HPV peut réduire le risque de verrues génitales, mais pas toutes les verrues." } }, { "@type": "Question", "name": "Faut-il éviter les lieux publics ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Évitez les douches publiques et les piscines pour réduire le risque de contagion." } }, { "@type": "Question", "name": "Les verrues peuvent-elles réapparaître après traitement ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est possible que les verrues réapparaissent, nécessitant un nouveau traitement." } }, { "@type": "Question", "name": "Comment renforcer le système immunitaire ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée, l'exercice régulier et le sommeil suffisant aident à renforcer l'immunité." } }, { "@type": "Question", "name": "Comment la podophyllotoxine est-elle administrée ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "La podophyllotoxine est généralement appliquée localement sur les verrues, en suivant les instructions du médecin." } }, { "@type": "Question", "name": "Quels sont les effets de la podophyllotoxine ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Elle agit en détruisant les cellules infectées par le virus, aidant à éliminer les verrues." } }, { "@type": "Question", "name": "Y a-t-il des alternatives à la podophyllotoxine ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, d'autres traitements incluent l'acide salicylique, la cryothérapie ou le laser." } }, { "@type": "Question", "name": "Combien de temps faut-il pour voir des résultats ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les résultats peuvent varier, mais une amélioration est souvent visible après quelques semaines." } }, { "@type": "Question", "name": "La podophyllotoxine est-elle sûre pour tous ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Non, elle est contre-indiquée chez les femmes enceintes et les personnes allergiques à ses composants." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les verrues ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des infections secondaires si les verrues sont irritées ou blessées." } }, { "@type": "Question", "name": "Les verrues peuvent-elles causer des cicatrices ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le traitement ou la manipulation des verrues peut entraîner des cicatrices permanentes." } }, { "@type": "Question", "name": "Y a-t-il des risques d'allergies à la podophyllotoxine ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines personnes peuvent développer des réactions allergiques à la podophyllotoxine." } }, { "@type": "Question", "name": "Les verrues peuvent-elles se propager à d'autres parties du corps ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les verrues peuvent se propager par auto-inoculation si elles sont touchées ou grattées." } }, { "@type": "Question", "name": "Les verrues peuvent-elles être cancéreuses ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les verrues communes ne sont pas cancéreuses, mais certaines verrues génitales peuvent être liées au cancer." } }, { "@type": "Question", "name": "Qui est le plus à risque de développer des verrues ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les enfants et les adolescents sont plus susceptibles de développer des verrues en raison de leur peau plus fine." } }, { "@type": "Question", "name": "Les personnes immunodéprimées sont-elles plus à risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes avec un système immunitaire affaibli sont plus susceptibles de développer des verrues." } }, { "@type": "Question", "name": "Le contact avec des verrues augmente-t-il le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le contact direct avec des verrues augmente le risque de transmission du virus." } }, { "@type": "Question", "name": "Les personnes ayant des antécédents de verrues sont-elles à risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes ayant des antécédents de verrues sont plus susceptibles d'en développer à nouveau." } }, { "@type": "Question", "name": "Les verrues sont-elles plus fréquentes chez certaines ethnies ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de preuve concluante que certaines ethnies soient plus à risque de verrues." } } ] } ] }

Sources (10000 au total)

A pan-cancer landscape of pathogenic somatic copy number variations.

Copy number variations (CNVs) play crucial roles in physiological and pathological processes, including cancer. However, the functional implications of somatic CNVs in tumor progression and evolution ... Starting from 7352 copy number profiles across 33 different cancer types, we infer the pathogenicity of each CNV and perform both intra- and inter-tumor analyses to predict the functional impact of di... Our analysis uncovered large heterogeneity among different tumors suggesting in many cases distinct genetic drivers of tumorigenesis. Recurrent genomic alterations frequently coincide with dysfunction... This study contributes to elucidate the functional impact of pathogenic CNVs in tumor progression and sheds light on their potential as prognostic markers in specific cancer types....

Contribution of copy number variations to the risk of severe eating disorders.

Eating disorders (EDs) are complex, multifactorial psychiatric conditions. Previous studies identified pathogenic copy number variations associated with NDDs (NDD-CNVs) in ED patients. However, no sta... Using array comparative genomic hybridization (aCGH), we conducted a high-resolution CNV analysis of 71 severe female ED patients and 1045 female controls. According to the American College of Medical... Of the samples analyzed with aCGH, 70 severe ED patients (98.6%) and 1036 controls (99.1%) passed our quality control filtering. We obtained 189 and 2539 rare CNVs from patients and controls, respecti... Our study provides the first preliminary evidence that NDD-CNVs may confer risk for severe EDs. The pathophysiology may involve synaptic dysfunction....

Prognostic and survival impact of BCL9 and RPS6KB1 copy number variation detected from circulating free DNA in hepatocellular carcinoma.

Circulating cell-free DNA (cfDNA) is a noninvasive substitute to liver biopsy for hepatocellular carcinoma (HCC) molecular profiling. This study aimed to use cfDNA to investigate copy number variation... Real-Time Polymerase Chain Reaction was used to determine the CNV and cfDNA integrity index in 100 HCC patients.... CNV gain in BCL9 and RPS6KB1 genes was detected in 14% and 24% of patients, respectively. Gain in CNV of BCL9 associated with risk of HCC in alcohol drinkers and hepatitis C seropositivity. In patient... cfDNA was used to detect BCL9 and RPS6KB1 CNVs, which influence prognosis and can be used as independent predictors of HCC patient survival....

Multiallelic Copy Number Variation in ORM1 is Associated with Plasma Cell-Free DNA Levels as an Intermediate Phenotype for Venous Thromboembolism.

Venous thromboembolism (VTE) is a common disease with high heritability. However, only a small portion of the genetic variance of VTE can be explained by known genetic risk factors. Neutrophil extrace...

Mitochondrial DNA copy number and risk of papillary thyroid carcinoma.

Mitochondrial DNA (mtDNA) copy number is associated with tumor activity and carcinogenesis. This study was undertaken to investigate mtDNA copy number in papillary thyroid cancer (PTC) tissues and to ... DNA was extracted from 105 PTC tissues and 67 control thyroid tissues, and mtDNA copy number mtDNA oxidative damage were determined using qPCR techniques.... Overall, the relative mtDNA copy number was significantly higher in PTC patients (p < 0.001). The risk of developing PTC increased significantly across the tertiles of mtDNA copy number (p trend < 0.0... Our results indicated that the augmentation of mtDNA content plays a significant role during the initiation of thyroid cancer, and it might represent a potential biomarker for predicting the risk of P...

Copy number variations (CNVs) and karyotyping analysis in males with azoospermia and oligospermia.

Considering the essential roles that genetic factors play in azoospermia and oligospermia, this study aims to identify abnormal chromosomes using karyotyping and CNVs and elucidate the associated gene... A total of 1157 azoospermia and oligospermia patients were recruited, of whom, 769 and 674 underwent next-generation sequencing (NGS) to identify CNVs and routine G-band karyotyping, respectively.... First, 286 patients were co-analyzed using CNV sequencing (CNV-seq) and karyotyping. Of the 725 and 432 patients with azoospermia and oligospermia, 33.8% and 48.9% had abnormal karyotypes and CNVs, re... Sex chromosome and autosomal CNV loci, such as Xp22.31 and 2p24.3, as well as the associated genes, such as VCX and NACAP9, could be candidate spermatogenesis genes. The high-frequency abnormal karyot...

dbCNV: deleteriousness-based model to predict pathogenicity of copy number variations.

Copy number variation (CNV) is a type of structural variation, which is a gain or loss event with abnormal changes in copy number. Methods to predict the pathogenicity of CNVs are required to realize ... From single nucleotide polymorphism (SNP), gene and region dimensions, we collected 79 informative features that quantitatively describe the characteristics of CNV, such as CNV length, the number of p... The performance of the dbCNV suggest that functional deleteriousness-based model of CNV is a promising approach to support the classification prediction and to further understand the pathogenic mechan...